For press inquiries click here to contact us.
The Top Life Science Investors Of The 2015 Midas List
The Huffington Post
New Possibilities For People Who Suffer From Nut Allergies
Foresite Capital Reloads With New $300M Late-Stage Biotech Fund
Health Care Venture Firm Foresite Capital Closes $300M Fund
The Business Journals
Foresite Capital Raises $100M To Invest In Late-Stage Healthcare Companies
Foresite Capital Management Closes $100 Million Growth Capital Fund To Finance Late-Stage Healthcare Companies
Foresite Capital Closes $100M Fund For Late-Stage Biotechs
Recognitions by unaffiliated third parties should not be construed as a current or past endorsement of Foresite Capital Management, LLC (“Foresite Capital”) or the private funds it manages. The rankings and recognitions published by Forbes are based on information prepared and submitted by Foresite Capital. Third party ratings are not representative of an individual investor’s investment results or the results of Foresite Capital and its funds. Past performance is no guarantee of future results. Please contact Foresite Capital for more detail on the criteria upon which the Forbes Midas List is based.